SG11201505508TA - Kv1.3 antagonists and methods of use - Google Patents

Kv1.3 antagonists and methods of use

Info

Publication number
SG11201505508TA
SG11201505508TA SG11201505508TA SG11201505508TA SG11201505508TA SG 11201505508T A SG11201505508T A SG 11201505508TA SG 11201505508T A SG11201505508T A SG 11201505508TA SG 11201505508T A SG11201505508T A SG 11201505508TA SG 11201505508T A SG11201505508T A SG 11201505508TA
Authority
SG
Singapore
Prior art keywords
antagonists
methods
Prior art date
Application number
SG11201505508TA
Inventor
Ellen Chi
Wilson Edwards
Chichi Huang
Wai-Ping Leung
Ronald Swanson
Alan Wickenden
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201505508TA publication Critical patent/SG11201505508TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
SG11201505508TA 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use SG11201505508TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756777P 2013-01-25 2013-01-25
US201361757389P 2013-01-28 2013-01-28
PCT/US2014/012932 WO2014116937A1 (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use

Publications (1)

Publication Number Publication Date
SG11201505508TA true SG11201505508TA (en) 2015-08-28

Family

ID=51228060

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505508TA SG11201505508TA (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use

Country Status (28)

Country Link
US (2) US10179808B2 (en)
EP (1) EP2948559B1 (en)
JP (1) JP6469590B2 (en)
KR (1) KR102268830B1 (en)
CN (1) CN104937105A (en)
AU (1) AU2014209227B2 (en)
BR (1) BR112015017795A2 (en)
CA (1) CA2898496A1 (en)
CY (1) CY1120481T1 (en)
DK (1) DK2948559T3 (en)
EA (1) EA037308B1 (en)
ES (1) ES2671434T3 (en)
HR (1) HRP20181055T1 (en)
HU (1) HUE039465T2 (en)
IL (1) IL239927B (en)
LT (1) LT2948559T (en)
MX (1) MX365987B (en)
NZ (1) NZ709913A (en)
PH (1) PH12015501627B1 (en)
PL (1) PL2948559T3 (en)
PT (1) PT2948559T (en)
RS (1) RS57422B1 (en)
SG (1) SG11201505508TA (en)
SI (1) SI2948559T1 (en)
TR (1) TR201809377T4 (en)
UA (1) UA117824C2 (en)
WO (1) WO2014116937A1 (en)
ZA (1) ZA201506131B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023072A1 (en) * 2014-08-15 2016-02-18 Monash University Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases
EP3265274B1 (en) 2015-03-05 2020-05-06 President and Fellows of Harvard College Compliant adaptive robot grasper
CA3022961A1 (en) 2016-05-02 2017-11-09 Tetragenetics, Inc. Anti-kv1.3 antibodies, and methods of production and use thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201808987A (en) * 2016-06-08 2018-03-16 健生生物科技公司 GM-CSF variants and methods of use
CN106589092A (en) * 2016-12-22 2017-04-26 中国科学技术大学先进技术研究院 Scorpion toxin polypeptide and method for preparing scorpion toxin polypeptide with similar natural physiological functions
CN106957357B (en) * 2017-04-01 2021-02-19 合肥科生景肽生物科技有限公司 Scorpion toxin polypeptide and synthetic method thereof
MX2022003300A (en) 2019-09-20 2022-07-13 Zealand Pharma As Kv1.3 blockers.
WO2022200374A1 (en) 2021-03-23 2022-09-29 Zealand Pharma A/S Kv1.3 blockers
WO2024083919A1 (en) 2022-10-18 2024-04-25 Zealand Pharma A/S Inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
WO1999014318A1 (en) 1997-09-16 1999-03-25 Board Of Regents, The University Of Texas System Method for the complete chemical synthesis and assembly of genes and genomes
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
JP5118969B2 (en) 2004-10-07 2013-01-16 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニア Analogs of ShK toxin in selective inhibition of Kv1.3 potassium channel and methods of use thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US7825093B2 (en) * 2006-10-25 2010-11-02 Amgen Inc. Methods of using OSK1 peptide analogs
CA2840407A1 (en) * 2007-05-22 2008-12-18 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US8716437B2 (en) * 2007-12-07 2014-05-06 Steven A. Goldstein Identification of toxin ligands
EP2328595A1 (en) * 2008-08-13 2011-06-08 The University Of British Columbia Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
US20120121591A1 (en) * 2009-03-20 2012-05-17 Amgen Inc. SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
HUE039465T2 (en) 2019-01-28
EP2948559A1 (en) 2015-12-02
NZ709913A (en) 2019-05-31
DK2948559T3 (en) 2018-05-28
JP6469590B2 (en) 2019-02-13
US10179808B2 (en) 2019-01-15
US20140255401A1 (en) 2014-09-11
JP2016505639A (en) 2016-02-25
AU2014209227A1 (en) 2015-07-30
US20190062383A1 (en) 2019-02-28
PH12015501627A1 (en) 2015-09-21
EP2948559B1 (en) 2018-05-02
HRP20181055T1 (en) 2018-09-07
IL239927B (en) 2020-10-29
EA201591380A1 (en) 2015-12-30
BR112015017795A2 (en) 2017-11-21
MX365987B (en) 2019-06-20
KR102268830B1 (en) 2021-06-24
PL2948559T3 (en) 2018-09-28
IL239927A0 (en) 2015-08-31
MX2015009632A (en) 2015-11-30
CN104937105A (en) 2015-09-23
AU2014209227B2 (en) 2017-11-23
ES2671434T3 (en) 2018-06-06
EA037308B1 (en) 2021-03-10
WO2014116937A1 (en) 2014-07-31
CY1120481T1 (en) 2019-07-10
EP2948559A4 (en) 2016-10-19
CA2898496A1 (en) 2014-07-31
PT2948559T (en) 2018-07-24
LT2948559T (en) 2018-06-25
KR20150108912A (en) 2015-09-30
SI2948559T1 (en) 2018-08-31
RS57422B1 (en) 2018-09-28
ZA201506131B (en) 2017-06-28
PH12015501627B1 (en) 2015-09-21
TR201809377T4 (en) 2018-07-23
UA117824C2 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
HRP20170888T1 (en) Tubulysin compounds, methods of making and use
HK1220373A1 (en) Il-33 antagonists and uses thereof il-33
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
IL246439A0 (en) Ring-contracted morphinans and the use thereof
HK1222778A1 (en) Medical device, and the methods of using same
ZA201506131B (en) Kv1.3 antagonists and methods of use
HK1200351A1 (en) Compositions comprising 15-hepe and methods of using the same 15-hepe
HK1250146A1 (en) Anti-pre-bcr antagonists and methods
HRP20181536T1 (en) Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
IL240248A0 (en) Met-binding agents and uses thereof
HK1223608A1 (en) Morphan and morphinan analogues, and methods of use
HK1246288A1 (en) S1pr2 antagonists and uses therefor
PT2980096T (en) 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof
ME03086B (en) Kv1.3 antagonists and methods of use
IL242818B (en) Il-1beta-il-1ra chimera and methods of using the same
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same